chrisvoncsefalvay/vaers-outcomes huggingface dataset:
81 yr/o male who presents to the ED with 10 days of flulike symptoms, worsening over the past 2 days. o He was initially seen 10 days ago by his PCP at community family center. o Was prescribed amoxicillin prophylactically, has been taking it as prescribed. o He has had 2 - Covid test at home. o He has had increasing phlegm over the past 2 days, white in color. o Exertional dyspnea. o Had diarrhea 5 days ago, vomiting 2 days ago, both of which have mostly resolved. o Has been taking Tylenol for body aches. o No history of COPD, asthma, or diabetes. o He does have a history of hypertension, on enalapril for that. o No abdominal pain. o Pain "in his lungs," more on the right, worse w deep breaths. o No leg swelling Review of Systems  Constitutional: Positive for appetite change, fatigue and fever. Negative for chills and diaphoresis.  HENT: Positive for congestion. Negative for ear pain, sore throat, rhinorrhea, neck pain and sinus pressure.   Eyes: Negative for discharge, redness and itching.  Respiratory: Positive for cough, chest tightness and shortness of breath.   Cardiovascular: Negative for chest pain and palpitations.  Gastrointestinal: Positive for diarrhea, nausea and vomiting. Negative for abdominal pain.  Genitourinary: Positive for decreased urine volume. Negative for dysuria.  Musculoskeletal: Positive for myalgias. Negative for arthralgias.  Skin: Negative for rash.  Neurological: Negative for light-headedness and headaches.  Psychiatric/Behavioral: Negative for confusion.
This case was reported by a other health professional via call center representative and described the occurrence of erythema in a 65-year-old female patient who received SHINGRIX (batch number C523T, expiry date 4th July 2020) for prophylaxis. On 5th June 2018, the patient received SHINGRIX (subcutaneous) .5 ml. On 5th June 2018, unknown after receiving SHINGRIX, the patient experienced intramuscular formulation administered by other route. On an unknown date, the patient experienced erythema and swelling. On an unknown date, the outcome of the erythema and swelling were not recovered/not resolved and the outcome of the intramuscular formulation administered by other route was unknown. It was unknown if the reporter considered the erythema, swelling and intramuscular formulation administered by other route to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The health care professional reported that the patient received SHINGRIX subcutaneously, which led to inappropriate route of vaccination. One to two days after injection, the patient experienced redness and swelling. The health care professional stated that the redness and swelling was getting better but now on 12th June 2018, it was starting to swell up again.
Got shot 8/16/10. Started with redness, pain & swelling 8/17/10. Seen given antibiotic. Seen 8/18/10 due to increase sx. Stop antbx, start warm to cool compresses, ALLEGRA BID and MOTRIN q 6 hrs. Saw 8/19/10 & decreased sx on exam.
This spontaneous report as received from a 60 year old female patient with allergies and without drug reactions/allergies refers to herself. On 11-APR-2013 the patient was vaccinated with a dose of ZOSTAVAX in the left arm (dose, route and lot # unspecified). On 12-APR-2013 the patient started to feel mild flu like symptoms which lasted a week (stopped on approximately 18-APR-2013), feel tired and just not feel well. The patient also mentioned she noticed a light pink spot around the injection site. The outcome of not feeling well, a light pink spot around the injection site and feeling tired was unknown. No lab diagnostics studies were performed. The patient did not seek medical attention. The relatedness of the events for ZOSTAVAX. Additional information has been requested.
From fax correspondence received at a manufacturer, it was reported that 3 county employees had reactions to the Imovax vaccine. All 3 women are improving as of 2/7/02. B) 1 had chills, shaking same day as vaccine. Remained tremulous thru 2/1/02.
Information has been received from a registered nurse concerning a 24 year old female zoo hoofstock/P.T., who on 05/27/04 was vaccinated with her third dose of the first series of hepatitis B virus vaccine rHBsAg (yeast). the does was given five years after the second dose. The employee did not experience any adverse reactions. However, following completion of the first of hepatitis B virus vaccine a titer was drawn and the result was 9.8, indeterminate. On 11/06/04 the employee, who had a recent sinus infection and antibiotic treatment, was again vaccinated intramuscularly in the left arm with a booster dose of hepatitis B virus vaccine rHBsAg (yeast). Concomitant therapy may have included Keflex. The employee called health services on Monday, 11/08/04, stating that she experienced transient numbness and tingling of left arm, left pinky and ring finger. The transient numbness and tingling was reportedly improved by 12:00 noon on 11/08/04. By Monday night, she experienced nausea without vomiting and went to bed. On Tuesday, 11/09/04 she had a temperature of 100 degrees, developed a sore throat, swollen glands, aches all over, tired and urinary symptoms. Over the counter flu medication was used. It has been reported that as of 11/16/04, the patient was recovered from the adverse experiences. Additional information is not expected.
Walking pneumonia, fever, cough, chills. Ten days. Rest, and water, over the counter drugs. After that, loss of smell, and taste. At this time has not returned. Doctor checking into it with my other RX's.
last noc about 8PM, pt began to notice severe itching on lt deltoid area & states it felt hot; this AM, noticed large edematous, erythematous area on deltoid (8xm x 7cm); states feel hot & itches;
pt recv vax 29APR99 & devel a swollen upper lip;pt had a mild URI @ the time vax was given;
1 of 2 pts who recvd vax w/in 48 hrs devel fever of 101, h/a, & inject site reaction (@ Pnu-imune site); inject site reaction described as localized redness & soreness;
day of soreness at injection site.  day 2 all touch to skin "hurt".  day 3 no skin "hurt", diarrhea, small round red splotch below injection site, hot to touch & swollen but not painful. day 4 same small spot.  day 5 red spot getting larger, Benadryl taken, but no hurt or itch, just hot to touch.  day 6 red spot larger but not as bright in color, Benadryl taken.
Expired dose administered; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired dose administered) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Jan-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Jan-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired dose administered). On 06-Jan-2022, EXPIRED PRODUCT ADMINISTERED (Expired dose administered) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment information were reported.  Some patients had reported flu like symptoms after receiving the vaccination but there were no details on that.
December 11th I had excruciating ear pain and it also felt blocked up. went to the doctor and I had an ear infection.  seemed to get worse so I went back to the doctor on dec 17th and then it got better after new round of medications.  on jan 6th 2022 I received my Moderna booster.  on jan 26, 2022 I developed left side bells palsey.  on jan 27 I went to the doctor and got diagnosed with it and prescribed medications and treatments. follow up visit on Feb 4th the dr stated I was 90 percent better and improved. I still had focal weakness blurred vision pain and redness in the eye.  (mild left eye fasciculations and very mild facial droop.  I would say it took about a month before I felt I was fully healed as I could be.  time to time still have tingles and weird sensations in and around mouth and cheek and eye area.
I'm a severe asthmatic with  diabetes, just started having breathing issues; This is a spontaneous report from contactable consumer. A 47-years-old male patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration, administered in Arm Right on 29Mar2021 09:00 (Batch/Lot Number: ER8732) as DOSE 1, SINGLE for covid-19 immunisation. Medical history included asthma, diabetes mellitus, osteoporosis, fibromyalgia from an unknown date and unknown if ongoing. Concomitant medication included ipratropium bromide, salbutamol sulfate (DUONEB) taken for an unspecified indication, start and stop date were not reported; venlafaxine hydrochloride (EFEXOR) taken for an unspecified indication, start and stop date were not reported; alendronate sodium (ALENDRONATE) taken for an unspecified indication, start and stop date were not reported; metformin (METFORMIN) taken for an unspecified indication, start and stop date were not reported; levocetirizine dihydrochloride (LEVOCETRIN) taken for an unspecified indication, start and stop date were not reported. The patient experienced that I am a severe asthmatic with diabetes, just started having breathing issues on 29Mar2021 20:30 with outcome of unknown.  No follow-up attempts are needed. No further information is expected.
FEW WEEKS AFTER RECEIVING THE VACCINE THE PATIENT EXPERIENCED PAIN IN LEFT SHOULDER, MRI DONE - ROTATOR CUFF TEAR
Patient went to store on 10/4/17 and had the pharmacist on duty look at the injection site which was raised and red around it. Pharmacist told her to watch and to make sure it didn't spread. Pt stopped in again on 10/5/17 and had other pharmacist look at it, stated that it seemed to be going down but still watch it and if not better go see the doctor.
PATIENT PRESENTED TO CLINIC WITH A NON-ITCHY, NON-TENDER RASH, NO VESICLES ON BACK. FOCUSED ON LEFT SIDE OF BACK (SAME SIDE AS INOCULATION). PATIENT NOTICED RASH ON 5/29/07.
pt. c/o of nausea and vomitting (vomited x1 the liquid drink that was injested earlier as reported by the patient) Patient reported slight dizziness.  Vitals: BP:116/74 Pulse: 84  RR:19 o2 sat 98% RA Advised to rest on gurney in sit up position and take sips of water for the nausea.  Monitored Vital signs.  pt no signs of SOB and no change of LOC.  Pt. alert and verbally responsive 10:07am Vitals: BP:124/79  Pulse: 69 RR:18  o2 97% RA Pt. went home and pt. stable and relief with symptoms noted.
Extreme muscle pain, heart palpitations, tachycardia, fever, chills, nausea, brain fog.  I was shaking so badly I could not hold a phone to call 911 and get help, and really my brain was in such a fog I could not think to do so.  All I could do is crawl back in bed and pray I didn't die.  I've never had a reaction to any vaccine before, and I thought this would actually kill me.  This lasted all night, and the next 3 days I was still very weak and sick.
Only given liquid vial; Only given liquid vial; This case was reported by a nurse via sales rep and described the occurrence of inappropriate preparation of medication in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK receipt date: 21-Nov-2022 Reporter's comment: The student health nurse shared that they had a medication error with the 2-vial presentation of Menveo. The reporter was only given liquid vial and the reporter asked to return to be revaccinated.  This lead to them switching to MenQuadfi since Menactra was no longer available. The reporter did not consent to follow-up. Additional supportive information: The patient only received liquid vial of Menveo, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered.
Red eyes, around eyes severe dark red, puffy, itchy, blotchy. Also blotchy severe red on neck.; Red eyes, around eyes severe dark red, puffy, itchy, blotchy. Also blotchy severe red on neck.; Red eyes, around eyes severe dark red, puffy, itchy, blotchy. Also blotchy severe red on neck.; Red eyes, around eyes severe dark red, puffy, itchy, blotchy. Also blotchy severe red on neck.; Red eyes, around eyes severe dark red, puffy, itchy, blotchy. Also blotchy severe red on neck.; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70-year-old female patient (not pregnant) received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 17Oct2023 at 15:00 as dose 1, single (Batch/Lot number: unknown) at the age of 70 years, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: TOPROL; MICROZIDE [GLICLAZIDE]; ESTRADIOL; ESCITALOPRAM. Past drug history included: Rocephin, reaction(s): "Allergy". Vaccination history included: Covid-19 vaccine (Dose 1, manufacturer unknown), for Covid-19 immunization; Covid-19 vaccine (Dose 3 (Booster), manufacturer unknown), for Covid-19 immunization. The following information was reported: ERYTHEMA (non-serious), OCULAR HYPERAEMIA (non-serious), PERIORBITAL SWELLING (non-serious), EYE PRURITUS (non-serious), RASH MACULAR (non-serious) all with onset 18Oct2023 at 02:00, outcome "not recovered" and all described as "Red eyes, around eyes severe dark red, puffy, itchy, blotchy. Also blotchy severe red on neck.". Therapeutic measures were not taken as a result of erythema, ocular hyperaemia, periorbital swelling, eye pruritus, rash macular.  Additional information: Patient had Red eyes, around eyes severe dark red, puffy, itchy, blotchy. Also blotchy severe red on neck. Patient nit had covid prior to vaccination and not tested covid post vaccination. Patient had not received any other vaccine in four weeks.  The information on the batch/lot number for bnt162b2 omi xbb.1.5 has been requested and will be submitted if and when received.
Severe chills, nausea, headache, debilitating joint swelling and pain approximately 24-36 hours after injection.
This spontaneous report as received from a nurse refers to a patient of unknown age and gender who on 15-NOV-2012 was vaccinated with a third dose of ROTATEQ after the vaccine expired (lot number reported as 0257AA, expiration date: 28-OCT-2012) (dose and route not reported). No other co-suspects were reported. No concomitant medications were reported. No treatment information was reported. No adverse reaction reported. Additional information is not expected.
9 days after first injection, patient reports left hand numbness, decrease in ability to distinguish temperature, pain. Paresthesias occur dorsal and palmar aspect of left hand, distal to wrist. No skin changes, intact pulses, normal strength. Injection site mildly swollen approximately 3cm, no erythema or fluctuance. Normal sensation of entire arm proximal to wrist. Also having some left sided upper back tightness.
Patient developed Varicella disease on 7-23-07 after having received Proquad 6-16-06
Had a raised temperature, redness and swelling at the injection site in her shoulder, and a hard lump under her skin at the injection site. The lump remains two years later. (At her  previous vaccinations at 6 mos, 4 mos, 2 mos: Dtap, Pneum7, IPV, HibHepB-Ped, she had the same symptoms including lumps under the skin at the injection sites in her thighs that lasted for many months.)
2/25/2021 9:30am minor pain at injection site upper left arm 2/26/2021 1:30pm dull headache, backside of head and very tired 2/26/2021 5:30pm minor tongue swelling, minor throat and nasal passage constriction 2/27/2021 9:30am  increased tongue swelling, increased throat and nasal passage constriction,  minor difficulty swallowing, minor facial swelling 2/27/2021 6:30pm  treatment at ER/Urgent Care with oral Prednisone tongue swelling started to decrease, released with Rx for Benadryl, Pepcid, Prednisone and EpiPen  2/27/2021 8:00pm started Benadryl + Pepcid. Tongue swelling decreased more, throat and nasal constriction starts to alleviate 3/1/2021 9:00am facial swelling continues with added redness to left side face and spot under right eye socket  3/1/2021 11:20am family doctor visit
high temp up to 104 w/in the 1st 12hr which persisted for 48hr;
fever; This spontaneous case was reported by a physician and describes the occurrence of PYREXIA (fever) in a 79-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Mar-2021, the patient experienced PYREXIA (fever). On 10-Mar-2021, PYREXIA (fever) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to US-MODERNATX, INC.-MOD-2021-083056 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-083056:
Moderna COVID-19 vaccine has been administered to patients post excursion.; Poor quality vaccine administered; Pediatric dose was given to adults mistakenly; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 vaccine has been administered to patients post excursion.), POOR QUALITY PRODUCT ADMINISTERED (Poor quality vaccine administered), WRONG PRODUCT ADMINISTERED (Pediatric dose was given to adults mistakenly) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR5186C) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 vaccine has been administered to patients post excursion.), POOR QUALITY PRODUCT ADMINISTERED (Poor quality vaccine administered), WRONG PRODUCT ADMINISTERED (Pediatric dose was given to adults mistakenly) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 vaccine has been administered to patients post excursion.), POOR QUALITY PRODUCT ADMINISTERED (Poor quality vaccine administered), WRONG PRODUCT ADMINISTERED (Pediatric dose was given to adults mistakenly) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 vaccine has been administered to patients post excursion.), POOR QUALITY PRODUCT ADMINISTERED (Poor quality vaccine administered) and WRONG PRODUCT ADMINISTERED (Pediatric dose was given to adults mistakenly).    Concomitant Medication use information was not provided by reporter.  It was reported that there was a temperature excursion between 26 May 2022 to 30 Sep 2022 and lot AR5186C was affected between 08 Sep 2022 to 27 Sep 2022. AR5186C was previously reported. Pediatric dose was given to adults mistakenly and were reported to CDPH, VAERS, CAIR and each patient that received the error dose, with instructions to re-vaccinate 2 months from the initial error dose. 051B22A was kept in the freezer upon receipt of shipment on 01-Aug-2022 and individual vials were put in the refrigerator on the day of use.  Treatment Medication use information was not provided by reporter.  This case contains information for the 71st of 104 patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2022-669791 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-669791:Master case
high fever; vomiting; This is a spontaneous report from a contactable physician via a Pfizer sales representative. A 16-year-old female patient received meningococcal group b rlp2086 (TRUMENBA), via an unspecified route of administration, on an unspecified date, at single dose, for immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced high fever and vomiting on an unspecified date with outcome of unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
This spontaneous report was received from a licensed vocational nurse and refers to an unspecified number of patients of unknown age and gender. On an unknown date, an unspecified number of patients were vaccinated with improperly stored GARDASIL (route of administrations, doses, lot numbers and expiry dates were not reported). It was reported that the vaccines were exposed to worst case 85F for 42.5 hours. No adverse effect was reported. This is one of several reports from the same reporter. Additional information has been requested.
Initial unsolicited report received from a nurse on 14 November 2014. A 54-year-old female patient had received a intramuscular dose of FLUZONE QIV (batch number UI159AB) in the left deltoid on 12 November 2014. There was no illness identified at time of vaccination. The reporter denied any medical conditions. The patient is allergic to nuts and "many other things". She is currently on an inhaler (no further details provided). On 12 November 2014, one hour after vaccination, the patient felt like her throat was swelling up, began to feel like there was smoke in her throat and she could not clear it, tightness in throat. Her voice became raspy. She took two BENADRYL and noticed some improvement. She went to the ER, was examined and released. Prednisone was administered. On examination, it was noted that the patient had swollen tonsils and adenoids as well as fluid behind left ear. Patient's outcome was reported as not recovered. Documents held by sender: none. Follow up information received from a health care professional on 15-DEC-2014: It was reported that the patient was not seen or treated by the doctor; the immunization was done in employee health. The patient was treated in Emergency room (ER).
Hospital Course: 1. Acute, recurrent abdominal pain. Lipase was just under twice the upper limit of normal. He was having epigastric area pain, which was worse with eating. Ordered for IV fluids, anti-emetics, and pain control. GI service consulted and acute pancreatitis was considered doubtful.  Pain resolved on follow-up today. Underwent EGD which noted duodenitis signs. Biopsies were taken. He is stable for discharge home with outpatient GI follow-up regarding biopsy results and further care plan. 2. Acute hypoglycemia. Resolved. Monitored labs. Encouraged PO intake. 3. Recent covid-19 infection. Had headache on 7-31 followed by runny nose and cough. These symptoms resolved. He tested positive at home on 8-1.Discussed with epidemiology and released from covid isolation. No specific treatment is currently needed.  4. Autistic spectrum disorder. He is to have outpatient follow-up. 5. DVT prophylaxis. He is low risk and ambulatory. Disposition: He is stable for discharge home with outpatient follow-up. Discussed management plan with patient at bedside and mother earlier today.
Began throwing PVC's on 10/5/08 sent to ER, EKG done, labwork, CXR sent home from ER with abnormal EKG saw cardiologist 10/9/08. US of heart normal.